Balaji Amines
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Balaji Amines is positioned for growth, driven by strategic capacity expansions and a focus on high-value specialty chemicals. Management's commentary highlights the commissioning of new projects, including Dimethyl Ether (DME) and Acetonitrile (ACN), which are expected to enhance production capacity and revenue. The company's emphasis on high-value products aligns with Vista's forecast of stable revenue growth and improving margins, supported by favorable domestic demand and government incentives for manufacturing. However, Balaji Amines faces challenges from volatile raw material prices and execution risks related to new capacities. The specialty chemicals industry is experiencing structural growth, which bodes well for Balaji Amines, although competitive pressures may limit pricing power. Over the next 12-24 months, key opportunities include the ramp-up of electronic grade DMC production for EV batteries and the expansion of its product portfolio. Conversely, watchpoints include geopolitical tensions affecting input costs and the need for effective scaling of new projects. Overall, Vista's outlook reflects cautious optimism, with a target price indicating limited upside potential in the near term
Why We Like This Stock
- Strategic capacity expansions in high-value specialty chemicals are expected to drive revenue growth
- Government incentives for domestic manufacturing enhance cost-effectiveness and market positioning
- Management projects significant volume growth and margin improvement, aligning with Vista's financial outlook
Things To Watch Out For
- Volatility in raw material prices poses risks to margins and profitability
- Execution risks related to the stabilization of new capacities could hinder growth
- Geopolitical tensions may impact demand and input costs, creating uncertainty
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,631 | 1,389 | 1,425 | 1,679 | 1,805 |
| Profit Before Tax (Cr.) | 302 | 213 | 232 | 357 | 359 |
| PBT Margin | 18.5% | 15.3% | 1628.1% | 21.3% | 19.9% |
| Net Profit (Cr.) | 232 | 169 | 184 | 285 | 283 |
| Earnings Per Share | 63.0 | 51.7 | 56.1 | 86.6 | 87.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BOB Capital Markets | ► Hold | 1,981 | 20-May-2026 |
| CD Equisearch | ▲ Buy | 3,327 | 10-Jul-2026 |
| Moneycontrol | ▲ Overweight | nan | 20-May-2026 |
Company Overview
Show Company Profile
Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India and internationally. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, choline chloride, mono-ethyl amine hydrochloride, and benzyl tri ethyl ammonium chloride; and pharma excipients, such as poly vinyl pyrrolidone. It also provides hotels, restaurants, and hospitality services. The company also exports its products to Europe, the United States, and Japan. Balaji Amines Limited was incorporated in 1988 and is headquartered in Hyderabad, India.